Skip to main content
Top
Published in: Annals of Surgical Oncology 12/2007

01-12-2007 | Breast Oncology

The Prognostic Significance of Micrometastases in Breast Cancer: A SEER Population-Based Analysis

Authors: Steven L. Chen, MD, MBA, Francesca M. Hoehne, MD, Armando E. Giuliano, MD

Published in: Annals of Surgical Oncology | Issue 12/2007

Login to get access

Abstract

Introduction

The prognostic significance of lymph node micrometastases in breast cancer is controversial. We hypothesized that the survival of patients with solely micrometastatic disease (N1mi) would be intermediate to patients with 1–3 tumor-positive lymph nodes (N1) and those with no positive lymph nodes (N0).

Methods

We queried the surveillance, epidemiology and end results (SEER) database for all patients between 1992 and 2003 with invasive ductal or lobular breast cancer without distant metastases and ≤3 axillary nodes with macroscopic disease. Patients were stratified by nodal involvement and compared using the Kaplan–Meier method. Cox proportional hazards regression was utilized to compare survival after adjusting for patient and tumor characteristics.

Results

Between 1992 and 2003, N1mi diagnoses increased from 2.3% to 7% among the 209,720 study patients (p < 0.001). In a T-stage stratified univariate analysis, N1mi patients had a worse prognosis in T2 lesions. On multivariate analysis, N1mi remained a significant prognostic indicator across all patients (p < 0.0001) with a hazard ratio of 1.35 compared to N0 disease and 0.82 compared to N1 disease. Other negative prognostic factors included male gender, estrogen-receptor negativity, progesterone-receptor negativity, lobular histology, higher grade, older age, higher T-stage, and diagnosis in an earlier time period.

Conclusion

Nodal micrometastasis of breast cancer carries a prognosis intermediate to N0 and N1 disease, even after adjusting for tumor- and patient-related factors. Prospective study is warranted and the results of pending trials are highly anticipated. Until then adjuvant therapy trials should consider using N1mi as a stratification factor when determining nodal status.
Literature
1.
go back to reference Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, et al. (Eds) AJCC Cancer Staging Manual 6th ed, 2002 Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, et al. (Eds) AJCC Cancer Staging Manual 6th ed, 2002
2.
go back to reference De Mascarel I, MacGrogan G, Picot V, Mathoulin-Pelissier S. Prognostic significance of immunohistochemically detected breast cancer node metastases in 218 patients. Br J Cancer 2002; 87:70–74PubMedCrossRef De Mascarel I, MacGrogan G, Picot V, Mathoulin-Pelissier S. Prognostic significance of immunohistochemically detected breast cancer node metastases in 218 patients. Br J Cancer 2002; 87:70–74PubMedCrossRef
3.
go back to reference Gillanders WE, Mikhitarian K, Hebert R, et al. Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study. Ann Surg 2004; 239:828–840PubMedCrossRef Gillanders WE, Mikhitarian K, Hebert R, et al. Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study. Ann Surg 2004; 239:828–840PubMedCrossRef
4.
go back to reference Masuda N, Tamaki Y, Sakita I, et al. Clinical significance of micrometastases in axillary lymph nodes assessed by reverse transcription-polymerase chain reaction in breast cancer patients. Clin Cancer Res 2000; 6:4176–4185PubMed Masuda N, Tamaki Y, Sakita I, et al. Clinical significance of micrometastases in axillary lymph nodes assessed by reverse transcription-polymerase chain reaction in breast cancer patients. Clin Cancer Res 2000; 6:4176–4185PubMed
5.
go back to reference Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220:391–398PubMedCrossRef Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220:391–398PubMedCrossRef
6.
go back to reference Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995; 394–401 Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995; 394–401
7.
go back to reference Van der Heiden-van der Loo M, Bezemer PD, Hennipman A, Siesling S, van Diest PJ, Bongers V, Peeters PH. Introduction of sentinel node biopsy and stage migration of breast cancer. Eur J Surg Oncol 2006; 32:710–714CrossRef Van der Heiden-van der Loo M, Bezemer PD, Hennipman A, Siesling S, van Diest PJ, Bongers V, Peeters PH. Introduction of sentinel node biopsy and stage migration of breast cancer. Eur J Surg Oncol 2006; 32:710–714CrossRef
8.
go back to reference Cserni G, Bianchi S, Vezzosi V, et al. The value of cytokeratin immunohistochemistry in the evaluation of axillary sentinel lymph nodes in patients with lobular breast carcinoma. J Clin Pathol 2006; 59:518–522PubMedCrossRef Cserni G, Bianchi S, Vezzosi V, et al. The value of cytokeratin immunohistochemistry in the evaluation of axillary sentinel lymph nodes in patients with lobular breast carcinoma. J Clin Pathol 2006; 59:518–522PubMedCrossRef
10.
go back to reference Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 195; 53:457–481 Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 195; 53:457–481
11.
go back to reference Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34:187–220 Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34:187–220
12.
go back to reference Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Eng J Med 2005; 353:793–802CrossRef Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Eng J Med 2005; 353:793–802CrossRef
13.
go back to reference Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, Hoon DS. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 2006; 24:4270–4276PubMedCrossRef Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, Hoon DS. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 2006; 24:4270–4276PubMedCrossRef
14.
go back to reference De Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 1992; 66:523–527PubMed De Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 1992; 66:523–527PubMed
15.
go back to reference Colpaert C, Vermeulen P, Jeuris W, et al. Early distant relapse in “node-negative” breast cancer patients is not predicted by occult axillary lymph node metastases, but by features of the primary tumour. J Pathol 2001; 193:442–449PubMedCrossRef Colpaert C, Vermeulen P, Jeuris W, et al. Early distant relapse in “node-negative” breast cancer patients is not predicted by occult axillary lymph node metastases, but by features of the primary tumour. J Pathol 2001; 193:442–449PubMedCrossRef
16.
go back to reference Millis RR, Springall R, Lee AH, Ryder K, Rytina ER, Fentiman IS. Occult axillary lymph node metastases are of no prognostic significance in breast cancer. Br J Cancer 2002; 86:396–401PubMedCrossRef Millis RR, Springall R, Lee AH, Ryder K, Rytina ER, Fentiman IS. Occult axillary lymph node metastases are of no prognostic significance in breast cancer. Br J Cancer 2002; 86:396–401PubMedCrossRef
17.
go back to reference Kahn HJ, Hanna WM, Chapman JA, et al. Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system. Breast J 2006; 12:291–293CrossRef Kahn HJ, Hanna WM, Chapman JA, et al. Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system. Breast J 2006; 12:291–293CrossRef
18.
go back to reference Reed W, Bohler PJ, Sandstad B, Nesland JM. Occult metastases in axillary lymph nodes as a predictor of survival in node negative breast carcinoma with long-term follow-up. Breast J 2004; 10:174–180PubMedCrossRef Reed W, Bohler PJ, Sandstad B, Nesland JM. Occult metastases in axillary lymph nodes as a predictor of survival in node negative breast carcinoma with long-term follow-up. Breast J 2004; 10:174–180PubMedCrossRef
19.
go back to reference Cummings MC, Walsh MD, Hohn BG, Bennett IC, Wright RG, McGuckin MA. Occult axillary lymph node metastases in breast cancer do matter: results of 10 year survival analysis. Am J Surg Pathol 2002; 26:1286–1295PubMedCrossRef Cummings MC, Walsh MD, Hohn BG, Bennett IC, Wright RG, McGuckin MA. Occult axillary lymph node metastases in breast cancer do matter: results of 10 year survival analysis. Am J Surg Pathol 2002; 26:1286–1295PubMedCrossRef
20.
go back to reference Cote RJ, Peterson HF, Chaiwun B, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999; 354:896–900PubMedCrossRef Cote RJ, Peterson HF, Chaiwun B, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999; 354:896–900PubMedCrossRef
21.
go back to reference Cserni G, Bianchi S, Boecker W, Decker T, Lacerda M, Rank F, Wells CA. Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer 2004; 103:358–367CrossRef Cserni G, Bianchi S, Boecker W, Decker T, Lacerda M, Rank F, Wells CA. Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer 2004; 103:358–367CrossRef
Metadata
Title
The Prognostic Significance of Micrometastases in Breast Cancer: A SEER Population-Based Analysis
Authors
Steven L. Chen, MD, MBA
Francesca M. Hoehne, MD
Armando E. Giuliano, MD
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 12/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9513-6

Other articles of this Issue 12/2007

Annals of Surgical Oncology 12/2007 Go to the issue